Memphasys Limited Achieves CE Mark Approval, Unlocking Commercial Scale for Felix System.
Memphasys Limited (ASX: MEM) has reached a critical commercial milestone with CE Mark approval for its Felix automated sperm selection system under EU MDR. This approval enables immediate commercial rollout across Europe and other CE-recognised markets, opening access to an addressable market exceeding €29 million annually. Importantly, CE certification activates previously secured multi-year commercial agreements in Europe and the Middle East, establishing Memphasys’ first contracted international revenue base. Early cartridge orders placed ahead of contractual obligations provide strong evidence of underlying clinic demand. Felix™ delivers a differentiated, automated alternative to traditional sperm preparation methods, offering improved efficiency, consistency and potential clinical outcomes for IVF clinics. With partners operationally prepared and a go-direct commercial strategy in execution, the company is positioned to scale recurring revenue across Europe and MENA. The CE Mark also accelerates regulatory pathways in India and Australia, supporting a broader global expansion strategy and reinforcing Memphasys’ transition into a revenue-scaling phase.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Memphasys Limited Achieves CE Mark Approval, Unlocking Commercial Scale for Felix System.
Memphasys Limited (ASX: MEM) has reached a critical commercial milestone with CE Mark approval for its Felix automated sperm selection system under EU MDR. This approval enables immediate commercial rollout across Europe and other CE-recognised markets, opening access to an addressable market exceeding €29 million annually. Importantly, CE certification activates previously secured multi-year commercial agreements in Europe and the Middle East, establishing Memphasys’ first contracted international revenue base. Early cartridge orders placed ahead of contractual obligations provide strong evidence of underlying clinic demand. Felix™ delivers a differentiated, automated alternative to traditional sperm preparation methods, offering improved efficiency, consistency and potential clinical outcomes for IVF clinics. With partners operationally prepared and a go-direct commercial strategy in execution, the company is positioned to scale recurring revenue across Europe and MENA. The CE Mark also accelerates regulatory pathways in India and Australia, supporting a broader global expansion strategy and reinforcing Memphasys’ transition into a revenue-scaling phase.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au